These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 28449621)

  • 1. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
    Ryan CJ; Saylor PJ; Everly JJ; Sartor O
    Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting bone metastases in prostate cancer: improving clinical outcome.
    Body JJ; Casimiro S; Costa L
    Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
    Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
    Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
    Vogelzang NJ
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Nilsson S
    Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
    Nilsson S
    Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
    Wilson JM; Parker C
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
    Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
    Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and pharmacokinetics of radium-223 in prostate cancer.
    Yeku O; Slovin SF
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):843-9. PubMed ID: 25740232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
    Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
    Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
    Shirley M; McCormack PL
    Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
    Nilsson S
    Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
    De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
    Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
    Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
    Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
    Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
    J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radium 223 dichloride for prostate cancer treatment.
    Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
    Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical guide to the use of radium 223 dichloride.
    Den RB; Doyle LA; Knudsen KE
    Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.